Loading...
XKRX
326030
Market cap5.33bUSD
Apr 02, Last price  
99,700.00KRW
1D
-1.68%
1Q
-8.20%
IPO
-39.58%
Name

SK Biopharmaceuticals Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
22.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
4.70%
Rev. gr., 5y
217.57%
Revenues
354.89b
+44.16%
37,631,486,14051,798,062,83060,454,791,13072,440,821,40071,416,701,94089,927,545,43085,316,069,9501,098,738,190123,852,416,02025,999,026,720418,644,529,120246,179,120,020354,891,555,520
Net income
-32.88b
L-76.42%
-19,465,137,000-30,330,598,000-41,001,914,000-37,048,875,000-28,061,186,000-30,360,843,000-97,649,060,000-138,096,479,000-71,519,466,820-247,413,613,86064,845,640,000-139,430,877,680-32,882,849,240
CFO
-94.20b
L-41.09%
-16,962,588,800-24,065,043,200-39,064,435,900-40,336,395,590-28,716,692,010-48,941,251,590-98,342,730,340-141,281,399,300-81,334,671,550-210,726,008,610-92,871,732,620-159,920,061,630-94,201,249,070
Earnings
May 07, 2025

Profile

SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.
URL
https://www.skbp.com/
IPO date
Jul 02, 2020
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
354,891,556
44.16%
246,179,120
-41.20%
Cost of revenue
286,083,665
272,906,388
Unusual Expense (Income)
NOPBT
68,807,890
(26,727,268)
NOPBT Margin
19.39%
Operating Taxes
(8,478,274)
(3,037,986)
Tax Rate
NOPAT
77,286,164
(23,689,281)
Net income
(32,882,849)
-76.42%
(139,430,878)
-315.02%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
57,060,819
5,644,021
Long-term debt
154,554,982
162,426,161
Deferred revenue
5
31,157,335
Other long-term liabilities
37,702,606
3,198,713
Net debt
(133,593,934)
(35,948,162)
Cash flow
Cash from operating activities
(94,201,249)
(159,920,062)
CAPEX
(3,249,365)
(5,960,948)
Cash from investing activities
225,272,591
(95,713,806)
Cash from financing activities
6,622,756
134,914,263
FCF
11,790,307
(46,143,844)
Balance
Cash
241,118,437
305,453,733
Long term investments
104,091,298
(101,435,389)
Excess cash
327,465,157
191,709,387
Stockholders' equity
(750,654,664)
(780,103,142)
Invested Capital
1,287,358,515
1,286,707,310
ROIC
6.00%
ROCE
12.78%
EV
Common stock shares outstanding
78,313
78,313
Price
Market cap
EV
EBITDA
84,125,334
(13,743,530)
EV/EBITDA
Interest
8,279,609
3,716,526
Interest/NOPBT
12.03%